Arima Genomics is advancing its Hi‑C‑based Aventa Lymphoma assay as an alternative to fluorescence in situ hybridization (FISH) for lymphoma diagnostics. The company published results showing Hi‑C sequencing can detect clinically significant gene fusions and rearrangements from FFPE lymphoma samples where FISH results were inconclusive or negative. Hi‑C preserves 3D genomic proximity information and can reveal structural variants across the genome without hypothesis‑driven panels. Arima argues Hi‑C offers higher signal amplification for rearrangement detection and a comprehensive genome‑wide readout versus targeted FISH panels, potentially simplifying workflows and reducing the need for multiple sequential tests. The technology is being commercialized through clinical assays and a clinical lab pipeline following a Series C financing. Adoption will hinge on clinical validation in larger cohorts, regulatory pathways, reimbursement, and integration into pathology workflows. If validated broadly, Hi‑C assays could reshape cytogenetic testing for cancer by offering a single assay to detect diverse structural events.